gp96 vaccine

The gp96 vaccine is an investigational immunotherapy that utilizes the heat shock protein gp96, often complexed with antigenic peptides derived from tumor or pathogen, to stimulate the immune system. Gp96 functions as a chaperone protein, binding and presenting antigens to antigen-presenting cells (APCs), thereby inducing robust, antigen-specific CD8+ T cell responses and promoting both innate and adaptive immunity[1][3][4][5][6][7][8][9]. Versions of the vaccine include autologous tumor-derived HSPPC-96 for cancer therapy and recombinant gp96-Ig vaccines for infectious disease targets[1][2][4][8]. Trials have covered a range of indications including recurrent glioma (glioblastoma), gastric cancer, non-small cell lung cancer, and infectious agents such as HIV, malaria, and SARS-CoV-2[1][2][4][8][9].

Other names

heat shock protein gp96 vaccineautologous gp96 vaccinegp96-Ig-based vaccinegp-96-Ig-based vaccinegp 96-Ig-based vaccineheat shock protein-peptide complex vaccine